BioInvent International AB(BOVNF)
$0.280.00 (0.00%)
BOVNF
BioInvent International AB stock drug pipeline
$0.28
At close:0.00 (0.00%)
BioInvent International AB (BOVNF) Drug Pipeline
5 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab (Keytruda®), Bi-1607, Ipilimumab (Yervoytm, 50 Mg/10 Ml Solution) | Melanoma, Melanoma Metastatic, Melanoma Of Skin, Melanoma Braf V600e/K Mutated, Melanoma Recurrent, Melanoma Stage Iii Or Iv, Melanoma Negative For Braf, Melanoma Negative For Nras, Melanomas, Uveal Melanoma, Metastatic | phase1AndPhase2 | Recruiting | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | Dec 16, 2024 | ― |
| Pembrolizumab, Bi-1910 | Non Small Cell Lung Cancer, Solid Tumors, Hepatocellular Carcinoma | phase1AndPhase2 | Recruiting | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | Dec 18, 2023 | ― |
| Trastuzumab, Bi-1607 | Metastatic Gastric Adenocarcinoma, Her2-Positive Metastatic Breast Cancer, Her2-Positive Breast Cancer, Her2-Positive Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma | phase1AndPhase2 | Terminated | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors | Sep 22, 2022 | ― |
| Bt-001, Pembrolizumab [Keytruda®] | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Metastatic Cancer, Merkel Cell Carcinoma, Soft Tissue Sarcoma | phase1AndPhase2 | Recruiting | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Jan 25, 2021 | ― |
| Bi-1808, Pembrolizumab (Keytruda® ) 25 Mg/Ml Solution For Injection | Ovarian Cancer, Melanoma, Advanced Malignancies, T-Cell Lymphoma | phase1AndPhase2 | Recruiting | BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | Dec 15, 2020 | ― |
| Bi1206 | Solid Tumor, Adult | phase1AndPhase2 | Recruiting | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04) | Oct 21, 2019 | ― |
| Rituximab, Acalabrutinib, Bi-1206 | Indolent B-Cell Non-Hodgkin Lymphoma | phase1AndPhase2 | Recruiting | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | May 17, 2018 | ― |
| Bi-505, High Dose Melphalan, Autologous Stem Cell Transplantation | Multiple Myeloma | phase1AndPhase2 | Terminated | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | Apr 18, 2016 | ― |
| Bi-505 | Smoldering Multiple Myeloma | Phase II | Terminated | A Phase II Study of BI-505 in Smoldering Multiple Myeloma | Mar 26, 2013 | ― |
| Mldl1278a, Statin, Stable Dose | Atherosclerosis | Phase II | Completed | A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER) | Dec 10, 2010 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab (Keytruda®), Bi-1607, Ipilimumab (Yervoytm, 50 Mg/10 Ml Solution) | phase1AndPhase2 | Melanoma, Melanoma Metastatic, Melanoma Of Skin, Melanoma Braf V600e/K Mutated, Melanoma Recurrent, Melanoma Stage Iii Or Iv, Melanoma Negative For Braf, Melanoma Negative For Nras, Melanomas, Uveal Melanoma, Metastatic | Recruiting | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | Dec 16, 2024 | ― |
| Pembrolizumab, Bi-1910 | phase1AndPhase2 | Non Small Cell Lung Cancer, Solid Tumors, Hepatocellular Carcinoma | Recruiting | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | Dec 18, 2023 | ― |
| Trastuzumab, Bi-1607 | phase1AndPhase2 | Metastatic Gastric Adenocarcinoma, Her2-Positive Metastatic Breast Cancer, Her2-Positive Breast Cancer, Her2-Positive Gastric Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma | Terminated | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors | Sep 22, 2022 | ― |
| Bt-001, Pembrolizumab [Keytruda®] | phase1AndPhase2 | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Metastatic Cancer, Merkel Cell Carcinoma, Soft Tissue Sarcoma | Recruiting | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Jan 25, 2021 | ― |
| Bi-1808, Pembrolizumab (Keytruda® ) 25 Mg/Ml Solution For Injection | phase1AndPhase2 | Ovarian Cancer, Melanoma, Advanced Malignancies, T-Cell Lymphoma | Recruiting | BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | Dec 15, 2020 | ― |
| Bi1206 | phase1AndPhase2 | Solid Tumor, Adult | Recruiting | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04) | Oct 21, 2019 | ― |
| Rituximab, Acalabrutinib, Bi-1206 | phase1AndPhase2 | Indolent B-Cell Non-Hodgkin Lymphoma | Recruiting | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | May 17, 2018 | ― |
| Bi-505, High Dose Melphalan, Autologous Stem Cell Transplantation | phase1AndPhase2 | Multiple Myeloma | Terminated | A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma | Apr 18, 2016 | ― |
| Bi-505 | Phase II | Smoldering Multiple Myeloma | Terminated | A Phase II Study of BI-505 in Smoldering Multiple Myeloma | Mar 26, 2013 | ― |
| Mldl1278a, Statin, Stable Dose | Phase II | Atherosclerosis | Completed | A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER) | Dec 10, 2010 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does BioInvent International AB (BOVNF) have in its pipeline
BioInvent International AB BOVNF is currently developing the following drugs: Pembrolizumab (Keytruda®), Bi-1607, Ipilimumab (Yervoytm, 50 Mg/10 Ml Solution), Pembrolizumab, Bi-1910, Trastuzumab, Bi-1607, Bt-001, Pembrolizumab [Keytruda®], Bi-1808, Pembrolizumab (Keytruda® ) 25 Mg/Ml Solution For Injection, Bi1206, Rituximab, Acalabrutinib, Bi-1206, Bi-505, High Dose Melphalan, Autologous Stem Cell Transplantation, Bi-505, Mldl1278a, Statin, Stable Dose, Tb-403. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

